NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $70,200 | -84.0% | 22,000 | -81.0% | 0.01% | -90.4% |
| Q2 2022 | $439,000 | -88.5% | 115,600 | -83.8% | 0.05% | -51.9% |
| Q1 2022 | $3,834,000 | +989.2% | 711,400 | +2636.2% | 0.11% | +1442.9% |
| Q4 2021 | $352,000 | +3.2% | 26,000 | +36.8% | 0.01% | -30.0% |
| Q3 2021 | $341,000 | -84.5% | 19,000 | -82.7% | 0.01% | -81.5% |
| Q1 2021 | $2,200,000 | +56.7% | 110,000 | +33.3% | 0.05% | +100.0% |
| Q4 2020 | $1,404,000 | +20.8% | 82,500 | +17.9% | 0.03% | -35.7% |
| Q3 2020 | $1,162,000 | – | 70,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |